Dr. Petrylak discussed how CRPC treatment has evolved from docetaxel to PSMA-targeted therapies, boosting median survival to 26 months. PSMA PET scans aid early care. Pembrolizumab shows 60–70% response rates. Bispecifics (Genex, AMG 180) and PARP inhibitors help in select patients. FDA-approved Lutetium PSMA offers 19.25-month benefit.